Decrease in CPA/EE users following risk minimization measures
A strong decrease in the use of cyproterone acetate (CPA) 2 mg, in combination with
A strong decrease in the use of cyproterone acetate (CPA) 2 mg, in combination with
PHARMO’s annual scientific report discusses the current expertise and research of the PHARMO Institute, publications,
Metformin is the most common initial type 2 diabetes (T2DM) treatment in the Netherlands, Italy,
Research confirms: concerns were justified Today the results of the study into the consequences of
In the current issue: A validated algorithm for asthma and COPD, ISO certificates for PHARMO and
Only 67% of high-cardiovascular-risk patients are treated with lipid-modifying therapy (LMT), of which only 7%
The reduction in HbA1c is greater in patients starting basal insulin or insulin glargine compared
Chemotherapy treatment for ovarian cancer (OC) is diverse, predominantly in later lines of treatment. There
In 2004 and 2008 studies showed that approximately 10.000-16.000 of the acute hospitalisations were related
The prevalence of diabetes in the Netherlands increased from 1.8% in 1999 to 4.9%